Deana Ferreri

Although the totality of the evidence is reassuring, the jury is still out on nonmedical switching to biosimilars, according to new study results.

European investigators say their analysis of court cases involving innovator monoclonal antibodies suggests secondary patents have generally failed to stop biosimilar competition.

Patients in an Australian clinic were generally open to using biosimilars but knew little about them, according to a recent study.